Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy

Clinical and Experimental Hypertension

Volumn 28, Issue 7, 2006, Pages 619-624

  Rubio Guerra, Alberto Francisco ^a,b,c   Lozano Nuevo, José Juan ^a   Vargas Ayala, Germán ^a   Rodríguez López, Leticia ^a   Ramos Brizuela, Luz María ^a   Escalante Acosta, Bruno Alfonso ^b  

^a Hospital General de Ticoman SS DF   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c NONE   (Mexico)

Author keywords

Combination therapy; Obesity; Trandolapril; Uncontrolled hypertension; Verapamil

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; OBESITY; SELF EXAMINATION; TREATMENT DURATION;

AGED; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; MEXICO; MIDDLE AGED; OBESITY; VASODILATOR AGENTS; VERAPAMIL;

EID: 33750062885     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/08860220600946087     Document Type: Article

References (13)

1. Rosas M, Lara A, Pastelín G, Velásquez O, Martínez J, Mendez A. Re-encuesta nacional de hipertensión arterial. Consolidación Mexicana de los factores de riesgo cardiovascular. Cohorte Nacional de Seguimiento. Arch Cardiol Mex 2005;75:96-111.
2. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity associated hypertension. New insights into mechanisms. Hypertension 2005;45:9-14.
3. The Seven Report of the Joint National Committee on Detection, Evaluation, and Treatment of high blood pressure. JNC 7. Complete version. Hypertension 2003;42:1206-1252.
4. Punzi HA, Novrit BA. The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. J Hum Hypertens. 1997;11:477-481.
5. Pepine CJ, Handberg EM, Cooper-Dehoff R, et al. A calcium antagonist versus a non-calcium antagonist hypertension-treatment strategy for patients with coronary artery disease (INVEST). JAMA 2003;290:2805-2816.
6. Rubio AF, Treviño CJ, Vargas G, Arceo A, Lozano JJ, Rodríguez L. Renoprotective effects of the combination trandolapril/verapamil in patients with type 2 diabetes mellitus and hypertension. Clin Drug Invest. 2002;22:541-546.
7. Dahlöf B, Sever P, Neil P, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipina adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. The Lancet 2005;366:895-906.
8. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
9. Aepfelbacher FC, Messerli FH, Nunez E. Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. Am J Cardiol. 1997;79:826-828.
10. Rubio AF, Arceo A, Vargas G, Rodríguez L, Lozano JJ, Treviño C. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004;27;1688-1691.
11. Calvo-Vargas CG, Padilla V, Troyo-Sanroman R. Loaned self-measurement equipment model compared with ambulatory blood pressure monitoring. Blood Pressure Monitoring 2003;8:63-70.
12. Julius S, Kjeldsen SE, Weber M. For the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartán or amlodipine: The VALUE randomized trial. The Lancet 2004;363:2022-2031.
13. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46:386-392.